Royalty Pharma plc
RPRX
Rang in Aktien
#875
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Aktienkurs
$61.92
Marktkapitalisierung
$27.57B
Veränderung (1 Tag)
2.74%
Veränderung (1 Jahr)
69.04%
Land
US
Handel Royalty Pharma plc (RPRX)
Kategorie
Healthcare
Dividendenrendite-Verlauf für Royalty Pharma plc (RPRX)
Dividendenrendite (TTM) von Royalty Pharma plc (Aktienkürzel: RPRX) zum 2023-12-31: 2.85%
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 2.37%
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 2.37%
Dividendenrendite-Verlauf für Royalty Pharma plc (RPRX) von 2015 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
| Jahr | Dividendenrendite | ändert |
|---|---|---|
| 2026 (TTM) | 1.57% | -52.57% |
| 2024 | 3.31% | 16.14% |
| 2023 | 2.85% | 47.67% |
| 2022 | 1.93% | 11.56% |
| 2021 | 1.73% | -15.61% |
| 2020 | 2.05% | -56.29% |
| 2019 | 4.69% | -9.28% |
| 2018 | 5.17% | 10.94% |
| 2017 | 4.66% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | Dividendenrendite | Land |
|---|---|---|
| 0.00% |
SE
|
|
| 0.00% |
FR
|
|
| 0.00% |
IT
|
|
| 0.00% |
US
|
|
| 2.29% |
HK
|
